Novel Compounds to Treat Dengue
The present invention is directed to the novel compounds, formula (I) and methods for flavivirus infection, such as the serotype 2 dengue viral infection in human body. The invention is based upon the in vitro implying the monolayer of HepG2 cells that was derived from human hepatomas which closely resembles the true target tissue of liver that was involved in the pathogenesis of dengue fever.
Contact person for this offer:
ChM Dr. Lee Ching Shya, PhD (Dual), RTTP
Technology Transfer Manager
Tel: +603-7967-7351/ 013-2250151